Kognitivnye narusheniya pri sakharnom diabete tipa 2
- Authors: Levin O.S1, Il'yasova F.N1
-
Affiliations:
- ГОУ ДПО Российская медицинская академия последипломного образования, Москва
- Issue: Vol 14, No 9 (2012)
- Pages: 92-97
- Section: Articles
- URL: https://bakhtiniada.ru/2075-1753/article/view/93766
- ID: 93766
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
O. S Levin
ГОУ ДПО Российская медицинская академия последипломного образования, МоскваКафедра неврологии
F. N Il'yasova
ГОУ ДПО Российская медицинская академия последипломного образования, МоскваКафедра неврологии
References
- Аметов А.С. Сахарный диабет 2 типа. Основы патогенеза и терапии. М., 2003.
- Дедов И.И., Шестакова М.В. Сахарный диабет. М., 2003.
- Левин О.С. Основные лекарственные средства, применяемые в неврологии. М.: МЕДпресс - информ, 2009.
- Левин О.С. Диагностика и лечение деменции в клинической практике. М.: МЕДпресс - информ, 2009.
- Яхно Н.Н., Захаров В.В., Локшина А.Б. и др. Танакан (EGb 761) в терапии умеренных когнитивных нарушений (многоцентровое исследование). Журн. неврол. и психиатр. 2006; 106 (12): 41–6.
- Abbatecola A.M., Rizzo M.R., Barbieri M et al. Postprandial plasma glucose excursions and cognitive functioning in aged type 2 diabetics. Neurology 2006; 67: 235–40.
- Ahlemeyer B, Krieglstein J. Pharmacological studies supporting the therapeutic use of Ginkgo biloba extract for Alzheimer’s disease. Pharmacopsych 2003; 36 (Suppl. 1): S8–S14.
- Alafuzoff I, Aho L, Helisalmi S et al. b - Amyloid deposition in brains of subjects with diabetes. Neuropathol Appl Neurobiol 2009; 35: 60–8.
- Arvanitakis Z et al. Diabetes is related to cerebral infarction but not to AD pathology in older persons. Neurology 2006; 67: 1960–5.
- Beeri M et al. Insulin in combination with other diabetes medication is associated with less Alzheimer neuropathology. Neurology 2008; 71: 750–7.
- Biessels G.J., Staekenborg S, Brunner E et al. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol 2006; 5: 64–74.
- Birks J, Grimley Evans J. Ginkgo biloba for cognitive impairment and dementia. Review. Cochrane Database Syst Rev 2007; 18 (2): 124–32.
- Craft S. The Role of Metabolic Disorders in Alzheimer Disease and Vascular Dementia. Arch Neurol 2009; 66: 300–5.
- De Kosky S.T., Williamson J.D., Fitzpatrick A.L. et al. Ginkgo biloba for prevention of dementia.A randomized controlled trial. JAMA 2008; 300: 2253–62.
- DCCT/EDIC Study Recearch Group. Long - Term effect of diabetes and its treatment on cognitive function. New Engl J Med 2007; 356: 1842–52.
- Dodge H.H., Zitzelberger T, Oken B.S. et al. A randomized placebo - controlled trial of Ginkgo biloba for the prevention of cognitive decline. Neurology 2008; 70: 1809–17.
- Eckert A, Keil U, Kressmann S et al. Effects of EGb761 Ginkgo biloba extract on mitochondrial function and oxidative stress. Pharmacopsych 2003; 36 (Suppl. 1): S15–S23.
- Irie F, Fitzpatrick A.L., Lopez O.L. Enhanced Risk for Alzheimer Disease in Persons With Type 2 Diabetes and APOE - 4. Arch Neurol 2008; 65: 89–93.
- Kalaria R.N. Diabetes, microvascular pathology and Alzheimer disease. Nature Rev. Neurology 2009; 5: 305–6.
- Le Bars P.L., Velasco F.M., Ferguson J.M. et al. Influence of the severity of cognitive impairment on the effect of the Ginkgo biloba extract EGb 761 in Alzheimer’s disease. Neuropsychobiol 2002; 45: 19–26.
- Luchsinger J.A., Tang M.X., Stern Y et al. Diabetes mellitus and risk of dementia in a multiethnic cohort. Am. J. Epidemiol 2001; 154: 635–41.
- Mac Knight C, Rockwood K, Awalt E et al. Diabetes mellitus and the risk of Alzheimer’s disease and vascular cognitive impairment in the Canadian Study of Health and Aging. Dement Geriatr Cogn Disord 2002; 14: 77–83.
- Mazza M, Capuano A, Bria P, Mazza S. Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer’s dementia in a randomized placebo – controlled double – blind study. Eur J Neurol 2006; 13 (9): 981–5.
- Musicco M, Palmer K, Salamone G et al. Predictors of progression of cognitive decline in Alzheimer’s disease: the role of vascular and sociodemographic factors. J Neurol 2009; 256: 1288–95.
- Mijnhout G.S., Scheltens P, Diamant M et al. Diabetic encephalopathy: a concept in need of a definition. Diabetologia 2006; 49: 1447–8.
- Nelson P.T. et al. Human cerebral neuropathology of type 2 diabetes mellitus. Biochim Biophys Acta 2008; 1792: 454–69.
- Oken B.S. Ginko biloba. In: Evidence - based Dementia Practice. Ed. by N.Qizilbash et al. Oxford: Blackwell Sciences 2002; 518–23.
- Schneider L.S., De Kosky S.T., Farlow M.R. A randomized, double - blind, placebo - controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer’s type. Curr Alzheimer Res 2005; 2 (5): 541–51.
- Sonnen J.A., Larson E.B., Brickell K et al. Different patterns of cerebral injury in dementia with or without diabetes. Arch Neurol 2009; 66: 315–22.
- Strachan M.W.J., Reynolds R.M., Frier B.M. The relationship between type 2 diabetes and dementia. British Medical Bulletin 2008; 88: 131–46.
- Van Harten B, de Leeuw F, Weinstein H C et al. Brain imaging in patients with diabetes: a systematic review. Diabetes Care 2006; 29: 2539–48.
- Van Harten B, Oosterman J, Muslimovic D et al. Cognitive impairment MRI correlates in the elderly patients with type 2 diabetes mellitus. Age and aging 2007; 36: 164–70.
- Vellas B, Andrieu S, Ousset P.J. et al. The GuidAge study. Methodological issues. Neurology 2006; 67 (Suppl. 3): S.6–S11.
- Volkow N.D., Logan J, Fowler J.S. et al. Association between age - related decline in brain dopamine activity and impairment in frontal and cingulate metabolism. Am J Psychiatry 2000; 157: 75–80.
- Volkow N.D., Logan J, Fowler J.S. et al. Association between age - related decline in brain dopamine activity and impairment in frontal and cingulate metabolism. Am J Psychiatry 2000; 157: 75–80.
Supplementary files
